| Patient | Benjamin Franklin |
|---|---|
| Date of birth | 1706-01-17 |
| Identifiers | MRN HR-EN004-SYN-TD; SSN (made up) 000-04-3318 |
| Document date | 1782-03-02 |
| Author | Lydia Penhallow, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
The patient attends this visit for primary care visit for recurrent gout flares and painful, interrupted urination with blood in the urine. [S]
Serum urate: 9.1 mg/dL (high); Sodium: 140 mmol/L; Potassium: 4.1 mmol/L; Bicarbonate (total CO2): 25 mmol/L; BUN: 22 mg/dL; Creatinine: 1.36 mg/dL (high); eGFR: 54 mL/min/1.73 m² (low); Glucose: 98 mg/dL; Calcium: 9.5 mg/dL; Phosphate: 3.4 mg/dL; Intact PTH: 52 pg/mL; 25-hydroxyvitamin D: 34 ng/mL; Hemoglobin: 14.2 g/dL; ALT: 24 U/L; LDL cholesterol: 128 mg/dL (high); HbA1c: 5.6%; Urine albumin-creatinine ratio: 18 mg/g; Urine pH: 5.2 [pH]; Urine red cells: 12 /[HPF] (high); Blood lead: 3.1 ug/dL; IPSS: 16; KFRE 2-year kidney failure risk: 0.2%; KFRE 5-year kidney failure risk: 0.6%. [S]
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1782-03-02 | Body height | 175 | cm | S |
| 1782-03-02 | Body weight | 96 | kg | S |
| 1782-03-02 | Body mass index (BMI) [Ratio] | 31.3 | kg/m2 | S |
| 1782-03-02 | Systolic blood pressure | 148 | mm[Hg] | S |
| 1782-03-02 | Diastolic blood pressure | 86 | mm[Hg] | S |
| 1782-03-02 | Heart rate | 74 | /min | S |
| 1782-03-02 | Respiratory rate | 16 | /min | S |
| 1782-03-02 | Body temperature | 36.7 | Cel | S |
| 1782-03-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1782-03-02 | Urate [Mass/volume] in Serum or Plasma | 9.1 | mg/dL | 3.5-7.2 mg/dL | High | S |
| 1782-03-02 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 1782-03-02 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1782-03-02 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 25 | mmol/L | 22-29 mmol/L | Normal | S |
| 1782-03-02 | Urea nitrogen [Mass/volume] in Serum or Plasma | 22 | mg/dL | 8-23 mg/dL | Normal | S |
| 1782-03-02 | Creatinine [Mass/volume] in Serum or Plasma | 1.36 | mg/dL | 0.74-1.35 mg/dL | High | S |
| 1782-03-02 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1777)/1.73 sq M | 54 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 1782-03-02 | Glucose [Mass/volume] in Serum or Plasma | 98 | mg/dL | 70-99 mg/dL | Normal | S |
| 1782-03-02 | Calcium [Mass/volume] in Serum or Plasma | 9.5 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1782-03-02 | Phosphate [Mass/volume] in Serum or Plasma | 3.4 | mg/dL | 2.5-4.5 mg/dL | Normal | S |
| 1782-03-02 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 52 | pg/mL | 15-65 pg/mL | Normal | S |
| 1782-03-02 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 | ng/mL | 30-100 ng/mL | Normal | S |
| 1782-03-02 | Hemoglobin [Mass/volume] in Blood | 14.2 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 1782-03-02 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-55 U/L | Normal | S |
| 1782-03-02 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 128 | mg/dL | <=99 mg/dL | High | S |
| 1782-03-02 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.6 | % | <=5.6% | Normal | S |
| 1782-03-02 | Albumin/Creatinine [Mass Ratio] in Urine | 18 | mg/g | <=30 mg/g | Normal | S |
| 1782-03-02 | pH of Urine | 5.2 | [pH] | 4.5-8 [pH] | Normal | S |
| 1782-03-02 | Erythrocytes [#/area] in Urine sediment by Microscopy high power field | 12 | /[HPF] | <=2 /[HPF] | High | S |
| 1782-03-02 | Lead [Mass/volume] in Blood | 3.1 | ug/dL | <=3.5 ug/dL | Normal | S |
| 1782-03-02 | International Prostate Symptom Score [IPSS] | 16 | {score} | S | ||
| 1782-03-02 | Kidney failure 2-year risk [Likelihood] by KFRE | 0.2 | % | S | ||
| 1782-03-02 | Kidney failure 5-year risk [Likelihood] by KFRE | 0.6 | % | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Hydrochlorothiazide 25 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1775-05-06 to 1782-03-02 | stopped | S |
| Losartan 50 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1782-03-02 | active | S |
| Allopurinol 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1782-03-02 to 1782-03-30 | completed | S |
| Colchicine 0.6 mg oral tablet, one tablet by mouth daily for flare prophylaxis | One tablet by mouth daily | Oral route | 1782-03-02 to 1782-09-14 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain, no more than 3 g a day | Two tablets every 6 hours as needed; maximum 6 tablets a day | Oral route | 1782-03-02 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Gout with recurrent flares, mostly in the right big toe, without tophi; synthetic modern diagnosis linked to his documented gout | active | confirmed | M1A.0710 | S — Synthetic modern diagnosis; his recurrent gout is documented in his own letters (D). |
| Bladder stone (2.6 cm, uric acid on analysis) with bladder outlet obstruction, removed by cystolitholapaxy; synthetic modern diagnosis linked to his documented stone | resolved | confirmed | N21.0 | S — Synthetic modern diagnosis confirmed by CT and cystoscopy; his stone is documented in his own letters (D), though its composition is not known. |
| Chronic kidney disease stage G3a A1 | active | confirmed | N18.31 | S — Synthetic diagnosis; no measure of kidney function from his lifetime exists. |
| Essential hypertension | active | confirmed | I10 | S — Synthetic diagnosis; no blood pressure from his lifetime exists. |